InvestorsHub Logo
Followers 20
Posts 5392
Boards Moderated 0
Alias Born 01/04/2012

Re: re-actor post# 8984

Sunday, 02/12/2012 3:50:02 PM

Sunday, February 12, 2012 3:50:02 PM

Post# of 26138
Actually, there were two patent applications, one of which indicates that Libigel's sexual dysfunction target is still on the table. Both applications also target Cardiovascular disease.

Methods for decreasing cardiovascular risk in postmenopausal women

Methods for treating sexual dysfunction while decreasing cardiovascular risk

I imagine more information on this will come out at the conference.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.